inclusion criteria: 1. confirmed sars-cov-2 infection 2. respiratory compromise requiring hospitalization for covid-19 disease as evidenced by at least one (or more) of the following criteria: * interstitial pneumonia on chest x-ray or high-resolution computed tomography (findings of consolidation or ground glass opacities), or * peripheral capillary oxygen saturation \< 94% on room air, or * requiring non-invasive supplemental oxygen (such as, nasal cannula, face mask) to maintain spo2 3. not requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ecmo) use at time of randomization 4. not participating in another clinical trial for the treatment of covid-19 disease through day 28

inclusion criteria: 1. confirmed sars-cov-2 infection 2. respiratory compromise requiring hospitalization for covid-19 disease as evidenced by at least one (or more) of the following criteria: * interstitial pneumonia on chest x-ray or high-resolution computed tomography (findings of consolidation or ground glass opacities), or * peripheral capillary oxygen saturation \< 94% on room air, or * requiring non-invasive supplemental oxygen (such as, nasal cannula, face mask) to maintain spo2 3. not requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ecmo) use at time of randomization 4. not participating in another clinical trial for the treatment of covid-19 disease through day 28

inclusion criteria: confirmed sars-cov-2 infection respiratory compromise requiring hospitalization for covid-19 disease as evidenced by at least one (or more) of the following criteria: interstitial pneumonia on chest x-ray or high-resolution computed tomography (findings of consolidation or ground glass opacities), or peripheral capillary oxygen saturation < 94% on room air, or requiring non-invasive supplemental oxygen (such as, nasal cannula, face mask) to maintain spo2 not requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ecmo) use at time of randomization not participating in another clinical trial for the treatment of covid-19 disease through day 28

inclusion criteria: confirmed sars-cov-2 infection respiratory compromise requiring hospitalization for covid-19 disease as evidenced by at least one (or more) of the following criteria: interstitial pneumonia on chest x-ray or high-resolution computed tomography (findings of consolidation or ground glass opacities), or peripheral capillary oxygen saturation < 94% on room air, or requiring non-invasive supplemental oxygen (such as, nasal cannula, face mask) to maintain spo2 not requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ecmo) use at time of randomization not participating in another clinical trial for the treatment of covid-19 disease through day 28

inclusion criteria: 1. confirmed sars-cov-2 infection 2. respiratory compromise requiring hospitalization for covid-19 disease as evidenced by at least one (or more) of the following criteria: - interstitial pneumonia on chest x-ray or high-resolution computed tomography (findings of consolidation or ground glass opacities), or - peripheral capillary oxygen saturation < 94% on room air, or - requiring non-invasive supplemental oxygen (such as, nasal cannula, face mask) to maintain spo2 3. not requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ecmo) use at time of randomization 4. not participating in another clinical trial for the treatment of covid-19 disease through day 28

inclusion criteria: 1. confirmed sars-cov-2 infection 2. respiratory compromise requiring hospitalization for covid-19 disease as evidenced by at least one (or more) of the following criteria: - interstitial pneumonia on chest x-ray or high-resolution computed tomography (findings of consolidation or ground glass opacities), or - peripheral capillary oxygen saturation < 94% on room air, or - requiring non-invasive supplemental oxygen (such as, nasal cannula, face mask) to maintain spo2 3. not requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ecmo) use at time of randomization 4. not participating in another clinical trial for the treatment of covid-19 disease through day 28

inclusion criteria: 1. age 40-85 years 2. confirmed sars-cov-2 infection 3. respiratory compromise requiring hospitalization for covid-19 disease as evidenced by at least one (or more) of the following criteria: - interstitial pneumonia on cxr or hrct (findings of consolidation or ground glass opacities), or - peripheral capillary oxygen saturation (spo2) < 94% on room air, or - requiring non-invasive supplemental oxygen (e.g., nasal cannula, face mask) to maintain spo2 4. not requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ecmo) use at time of randomization 5. not participating in another clinical trial for the treatment of covid-19 disease through day 28

inclusion criteria: 1. age 40-85 years 2. confirmed sars-cov-2 infection 3. respiratory compromise requiring hospitalization for covid-19 disease as evidenced by at least one (or more) of the following criteria: - interstitial pneumonia on cxr or hrct (findings of consolidation or ground glass opacities), or - peripheral capillary oxygen saturation (spo2) < 94% on room air, or - requiring non-invasive supplemental oxygen (e.g., nasal cannula, face mask) to maintain spo2 4. not requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ecmo) use at time of randomization 5. not participating in another clinical trial for the treatment of covid-19 disease through day 28